as 12-26-2024 4:00pm EST
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, and ClearPoint Therapeutic Solutions.
Founded: | 1998 | Country: | United States |
Employees: | N/A | City: | SOLANA BEACH |
Market Cap: | 337.6M | IPO Year: | N/A |
Target Price: | $12.00 | AVG Volume (30 days): | 230.2K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.69 | EPS Growth: | N/A |
52 Week Low/High: | $5.11 - $17.47 | Next Earning Date: | 11-07-2024 |
Revenue: | $30,429,000 | Revenue Growth: | 36.34% |
Revenue Growth (this year): | 35.56% | Revenue Growth (next year): | 21.86% |
CLPT Breaking Stock News: Dive into CLPT Ticker-Specific Updates for Smart Investing
ACCESSWIRE
a month ago
Simply Wall St.
2 months ago
ACCESSWIRE
2 months ago
GuruFocus.com
2 months ago
Simply Wall St.
2 months ago
ACCESSWIRE
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
4 months ago
The information presented on this page, "CLPT ClearPoint Neuro Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.